皮塞阿托纳尔改善了阿尔茨海默病小鼠的记忆能力和认知行为
Nan Zhang1, Ying Liu2, Yinuo Guan3
1Department of Neurology, Jilin Province Neuropsychiatric Hospital, Siping, China.
Neurological research
|November 13, 2025
概括
在阿尔茨海默氏症小鼠模型中,Piceatannol (PIC) 治疗改善了认知功能,并减少了氧化应激.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特点是氧化压力和认知能力下降.
- 天然多的Piceatannol (PIC) 已证明具有抗氧化特性,但其在AD模型中的有效性需要进一步研究.
研究的目的:
- 评估不同剂量的Piceatannol (PIC) 在已建立的阿尔茨海默病 (AD) 鼠标模型中的治疗潜力.
- 评估PIC对AD小鼠氧化应激标志物和认知功能的影响.
主要方法:
- 使用D-gal和AlCl3.3诱导了一种阿尔茨海默病小鼠模型.
- 60只小鼠被分为对照组,AD模型,多尼佩西尔治疗组和3个PIC治疗组 (低剂量,中剂量,高剂量).
- 用不同剂量的PIC进行了35天的治疗,随后进行了认知和生化评估.
主要成果:
- 在AD小鼠中,Piceatannol治疗显著降低了逃逸延迟和增加了平台交叉,表明认知功能得到改善.
- 在AD小鼠中,PIC的使用提高了抗氧化酶超氧化脱氧化酶 (SOD) 和谷氨过氧化酶 (GSH-Px) 的水平,同时降低了甲 (MDA).
- 观察到的效应是剂量依赖的,高剂量PIC组显示出最显著的改善.
结论:
- 在阿尔茨海默病小鼠模型中,Piceatannol显示出对氧化应激和认知障碍的显著神经保护作用.
- 在研究的AD模型中,PIC治疗改善了记忆和认知,减轻了氧化组织损伤,并表现出最小的器官毒性.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


